Htg Molecular Diagnostics
Htg Molecular Diagnostics is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
C4971006: A PHASE 1b/2, OPEN-LABEL STUDY OF PF-07901801 IN COMBINATION WITH GLOFITAMAB AFTER A FIXED, SINGLE DOSE OF OBINUTUZUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION
Sponsor Pfizer Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Sponsor Bristol Myers Squibb International Corporation
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Htg Molecular Diagnostics?
The 2026-10-09 snapshot links Htg Molecular Diagnostics to 4 distinct CTIS trials. Recorded services include EdgeSeq Assay for Oncology Biomarker Panel (OBP), provided with tissue FFPE and an H&E slides, EdgeSeq Assay for Oncology Biomarker Panel (OBP), provided with tissue FFPE and H&E slides, HTG EdgeSeq Immuno-Oncology Assay in selected tissue samples, Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Htg Molecular Diagnostics?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Htg Molecular Diagnostics conducted?
The linked trials record locations in 14 countries, including Germany, Spain, France, Austria, Denmark. These are trial locations, not confirmed office locations or countries where Htg Molecular Diagnostics delivered services.
What can this page tell me about Htg Molecular Diagnostics's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Htg Molecular Diagnostics. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Htg Molecular Diagnostics Inc.